Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Ani Pharmaceuticals Inc (ANIP)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Ani Pharmaceuticals Inc.
Table 2 shows the detailed insider transactions.
This company's CIK number is 1023024.
Total stock buying since 2015: $2,334,855.
Total stock sales since 2015: $211,720,298.
Total stock option exercises since 2015: $9,126,408.
Table 3. Detailed insider trading at Ani Pharmaceuticals Inc (ANIP)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2026-05-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 500 | 78.16 | 39,080 |
| 2026-05-13 | Walsh Patrick D | Sale | 10,000 | 80.63 | 806,300 |
| 2026-05-12 | Gutwerg Ori (SVP, GENERICS) | Sale | 2,772 | 79.50 | 220,374 |
| 2026-05-12 | Rowland Thomas Andrew (SVP, HEAD - ESTABLISHED BRANDS) | Sale | 459 | 79.21 | 36,357 |
| 2026-05-11 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 55,000 | 77.57 | 4,266,350 |
| 2026-05-11 | Walsh Patrick D | Sale | 3,973 | 80.75 | 320,819 |
| 2026-04-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 500 | 77.95 | 38,975 |
| 2026-03-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 500 | 72.62 | 36,310 |
| 2026-03-13 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 3,162 | 71.64 | 226,525 |
| 2026-03-11 | Rowland Thomas Andrew (SVP, HEAD - ESTABLISHED BRANDS) | Sale | 4,772 | 74.91 | 357,470 |
| 2026-03-09 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 5,087 | 74.13 | 377,099 |
| 2026-03-09 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 3,602 | 74.18 | 267,196 |
| 2026-03-06 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,485 | 75.00 | 111,375 |
| 2026-03-06 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 2,121 | 74.22 | 157,420 |
| 2026-03-05 | Carey Stephen P. (SVP & CFO) | Sale | 7,312 | 75.49 | 551,982 |
| 2026-03-05 | Carey Stephen P. (SVP & CFO) | Option Ex | 3,312 | 49.51 | 163,977 |
| 2026-03-03 | Gutwerg Ori (SVP, GENERICS) | Sale | 2,060 | 76.50 | 157,590 |
| 2026-03-03 | Walsh Patrick D | Sale | 6,000 | 74.23 | 445,380 |
| 2026-03-02 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 417 | 74.00 | 30,858 |
| 2026-02-20 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,730 | 77.99 | 134,922 |
| 2026-02-20 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 5,323 | 78.02 | 415,300 |
| 2026-02-19 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 2,084 | 77.53 | 161,572 |
| 2026-02-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 500 | 76.80 | 38,400 |
| 2026-02-12 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 7,032 | 76.55 | 538,299 |
| 2026-01-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 500 | 84.33 | 42,165 |
| 2025-12-18 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,622 | 82.40 | 133,652 |
| 2025-12-12 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 82.32 | 32,928 |
| 2025-12-05 | Tannenbaum Renee P | Sale | 1,800 | 81.15 | 146,070 |
| 2025-11-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 87.27 | 34,908 |
| 2025-11-13 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 94 | 88.00 | 8,272 |
| 2025-11-13 | Walsh Patrick D | Sale | 8,643 | 86.88 | 750,903 |
| 2025-11-12 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 14,642 | 89.07 | 1,304,162 |
| 2025-10-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 90.09 | 36,036 |
| 2025-09-19 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,000 | 98.04 | 98,040 |
| 2025-09-12 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 98.42 | 39,368 |
| 2025-09-03 | Pera Antonio R | Sale | 7,292 | 94.94 | 692,302 |
| 2025-08-25 | Leonard Matthew J (Director) | Sale | 2,528 | 90.62 | 229,087 |
| 2025-08-22 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,763 | 91.10 | 160,609 |
| 2025-08-21 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 52,988 | 90.44 | 4,792,234 |
| 2025-08-20 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 47,012 | 90.27 | 4,243,773 |
| 2025-08-20 | Pera Antonio R | Sale | 5,421 | 89.73 | 486,426 |
| 2025-08-18 | Thoma Jeanne | Sale | 21,540 | 89.31 | 1,923,845 |
| 2025-08-18 | Leonard Matthew J (Director) | Sale | 6,937 | 88.17 | 611,635 |
| 2025-08-15 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 86.97 | 1,739,400 |
| 2025-08-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 52,990 | 87.15 | 4,618,078 |
| 2025-08-15 | Walsh Patrick D | Sale | 9,000 | 89.05 | 801,450 |
| 2025-08-14 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 47,010 | 89.48 | 4,206,454 |
| 2025-08-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 88.87 | 35,548 |
| 2025-08-12 | Gutwerg Ori (SVP, GENERICS) | Sale | 5,873 | 86.53 | 508,190 |
| 2025-08-12 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 56,960 | 85.93 | 4,894,572 |
| 2025-08-12 | Carey Stephen P. (SVP & CFO) | Sale | 50,000 | 86.07 | 4,303,500 |
| 2025-08-12 | Carey Stephen P. (SVP & CFO) | Option Ex | 50,000 | 46.49 | 2,324,500 |
| 2025-08-12 | Rowland Thomas Andrew (SVP, HEAD - ESTABLISHED BRANDS) | Sale | 4,975 | 85.71 | 426,407 |
| 2025-08-12 | Haughey Thomas | Sale | 19,341 | 85.93 | 1,661,972 |
| 2025-07-14 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 64.88 | 25,952 |
| 2025-05-15 | Gutwerg Ori (SVP, GENERICS) | Sale | 881 | 60.07 | 52,921 |
| 2025-05-14 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 4,000 | 60.45 | 241,800 |
| 2025-05-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 62.20 | 24,880 |
| 2025-05-09 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 700 | 76.83 | 53,781 |
| 2025-04-14 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 68.96 | 27,583 |
| 2025-03-19 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,866 | 65.00 | 121,290 |
| 2025-03-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 63.33 | 25,332 |
| 2025-03-07 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,000 | 60.86 | 60,860 |
| 2025-03-05 | Gutwerg Ori (SVP, GENERICS) | Sale | 5,384 | 60.02 | 323,120 |
| 2025-03-05 | Gutwerg Ori (SVP, GENERICS) | Option Ex | 300 | 31.49 | 9,447 |
| 2025-02-21 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,000 | 60.20 | 60,200 |
| 2025-02-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 800 | 59.54 | 47,632 |
| 2025-01-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 53.92 | 21,568 |
| 2024-12-17 | Carey Stephen P. (SVP & CFO) | Sale | 7,500 | 55.79 | 418,425 |
| 2024-12-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 56.24 | 14,060 |
| 2024-12-11 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,000 | 60.00 | 60,000 |
| 2024-11-26 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 33,481 | 58.12 | 1,946,083 |
| 2024-11-26 | Lalwani Nikhil (PRESIDENT & CEO) | Option Ex | 30,000 | 29.00 | 870,000 |
| 2024-11-15 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 6,500 | 57.70 | 375,050 |
| 2024-11-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 61.36 | 15,340 |
| 2024-10-14 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 57.19 | 14,297 |
| 2024-09-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 56.82 | 14,205 |
| 2024-08-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 59.62 | 14,905 |
| 2024-07-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 2,743 | 62.00 | 170,066 |
| 2024-07-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 14,257 | 63.16 | 900,472 |
| 2024-07-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 22,000 | 64.27 | 1,413,940 |
| 2024-07-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,000 | 63.38 | 697,180 |
| 2024-07-12 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 64.91 | 16,227 |
| 2024-07-01 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 63.44 | 1,268,800 |
| 2024-06-21 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 20,000 | 58.90 | 1,178,000 |
| 2024-06-20 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,447 | 59.86 | 685,217 |
| 2024-06-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,607 | 60.76 | 644,481 |
| 2024-06-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 7,946 | 61.41 | 487,963 |
| 2024-06-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 63.80 | 15,950 |
| 2024-06-07 | Marken James G. (SVP OPS & PROD DEV) | Option Ex | 12,550 | 53.28 | 668,726 |
| 2024-06-05 | Gutwerg Ori (SVP, GENERICS) | Sale | 2,985 | 67.00 | 199,995 |
| 2024-06-04 | Carey Stephen P. (SVP & CFO) | Sale | 5,000 | 63.58 | 317,900 |
| 2024-06-03 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 64.41 | 1,288,200 |
| 2024-05-21 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 2,000 | 61.61 | 123,220 |
| 2024-05-20 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 12,855 | 61.81 | 794,567 |
| 2024-05-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 5,836 | 62.09 | 362,357 |
| 2024-05-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 16,459 | 63.84 | 1,050,742 |
| 2024-05-16 | Tannenbaum Renee P | Sale | 2,000 | 63.87 | 127,740 |
| 2024-05-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 14,850 | 65.86 | 978,021 |
| 2024-05-14 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 16,669 | 66.10 | 1,101,820 |
| 2024-05-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 67.69 | 16,922 |
| 2024-05-01 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 66.62 | 1,332,400 |
| 2024-04-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 16,809 | 65.17 | 1,095,442 |
| 2024-04-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,423 | 64.98 | 677,286 |
| 2024-04-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 9,520 | 65.40 | 622,608 |
| 2024-04-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 5,834 | 66.20 | 386,210 |
| 2024-04-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 7,414 | 66.33 | 491,770 |
| 2024-04-12 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 67.79 | 16,947 |
| 2024-04-01 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 67.25 | 1,345,000 |
| 2024-03-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 66.54 | 16,635 |
| 2024-03-11 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 65.81 | 1,316,200 |
| 2024-03-11 | Carey Stephen P. (SVP & CFO) | Sale | 7,787 | 65.55 | 510,437 |
| 2024-03-08 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,000 | 67.17 | 671,700 |
| 2024-03-08 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 16,292 | 67.13 | 1,093,681 |
| 2024-03-07 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 15,085 | 66.35 | 1,000,889 |
| 2024-03-07 | Marken James G. (SVP OPS & PROD DEV) | Sale | 24,338 | 66.37 | 1,615,313 |
| 2024-03-06 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 14,822 | 65.47 | 970,396 |
| 2024-03-06 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 28,965 | 65.52 | 1,897,786 |
| 2024-03-05 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,093 | 65.35 | 659,577 |
| 2024-03-05 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 5,000 | 66.00 | 330,000 |
| 2024-03-04 | Pera Antonio R | Sale | 7,000 | 65.20 | 456,400 |
| 2024-02-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 56.04 | 14,010 |
| 2024-01-23 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 15,000 | 56.44 | 846,600 |
| 2024-01-22 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 5,692 | 55.95 | 318,467 |
| 2024-01-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 4,524 | 55.57 | 251,398 |
| 2024-01-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 9,784 | 55.30 | 541,055 |
| 2024-01-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,000 | 55.11 | 551,100 |
| 2024-01-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 5,000 | 55.63 | 278,150 |
| 2024-01-12 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 56.43 | 14,107 |
| 2023-12-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 25,000 | 52.65 | 1,316,250 |
| 2023-12-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 13,026 | 52.44 | 683,083 |
| 2023-12-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,974 | 52.44 | 627,916 |
| 2023-12-11 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 49.21 | 12,302 |
| 2023-11-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 13,000 | 51.00 | 663,000 |
| 2023-11-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 6,448 | 51.66 | 333,103 |
| 2023-11-15 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 2,622 | 53.81 | 141,089 |
| 2023-11-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 7,647 | 53.64 | 410,185 |
| 2023-11-14 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 22,095 | 53.17 | 1,174,791 |
| 2023-11-10 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 3,000 | 52.47 | 157,410 |
| 2023-10-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,000 | 57.06 | 570,600 |
| 2023-10-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 6,242 | 57.78 | 360,662 |
| 2023-10-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 8,758 | 58.53 | 512,605 |
| 2023-10-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 13,063 | 58.31 | 761,703 |
| 2023-10-13 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,937 | 57.58 | 687,332 |
| 2023-10-02 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 56.48 | 1,129,600 |
| 2023-09-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 25,333 | 61.23 | 1,551,139 |
| 2023-09-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 8,425 | 61.64 | 519,317 |
| 2023-09-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 16,242 | 62.81 | 1,020,160 |
| 2023-09-01 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 64.70 | 1,294,000 |
| 2023-08-29 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 25,000 | 63.37 | 1,584,250 |
Insider trading activities including stock purchases, stock sales, and option exercises
of ANIP listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Ani Pharmaceuticals Inc (symbol ANIP,
CIK number 1023024) see
the Securities and Exchange Commission (SEC) website.